Your SlideShare is downloading. ×
Wyeth Remake Analyst Meeting 10-05-06 slides 4-8
Wyeth Remake Analyst Meeting 10-05-06 slides 4-8
Wyeth Remake Analyst Meeting 10-05-06 slides 4-8
Wyeth Remake Analyst Meeting 10-05-06 slides 4-8
Wyeth Remake Analyst Meeting 10-05-06 slides 4-8
Wyeth Remake Analyst Meeting 10-05-06 slides 4-8
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Wyeth Remake Analyst Meeting 10-05-06 slides 4-8

750

Published on

Published in: Business, Economy & Finance
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
750
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Remake of October 5, 2006 Wyeth Analyst Meeting slides 4-8 http://phx.corporate-ir.net/phoenix.zhtml?c=78193&p=irol-presentations
  • 2. Agenda 4 Break New Products U. Wiinberg Enbrel® & Prevnar® E.A. Emini, Ph.D. Prevnar 13 R. Essner Introduction J. Victoria Welcome Tygacil® J.S. Camardo, M.D. Torisel™ Lybrel™ G. Constantine, M.D. Aprela™ / Viviant™ J.S. Camardo, M.D. Methylnaltrexone R.M. Poole, M.D., FACP Bifeprunox J.M. Mahady Pristiq™ B. Poussot Conclusion and Q&A Key Registration Submissions R.R. Ruffolo, Jr., Ph.D. Mid-Pipeline Review
  • 3. Introduction 5 Robert Essner Chairman and Chief Executive Officer, Wyeth
  • 4. Wyeth Past Business Performance 7% 3% 9% 10% 8% Revenue Growth (in billions) 6 WHI
  • 5. Wyeth Past Business Performance 11% 15% 2% 10% 7% EPS* Growth 7 WHI July Guidance * Before Certain Significant items
  • 6. EPS Continues to Grow in 2006 12% 11% 15% 2% 10% 7% EPS* Growth 8 WHI +** July Guidance * Before Certain Significant items ** When Adjusted for Stock Option Expensing in 2005

×